Refine by
Life Sciences And Health Care Articles & Analysis
126 news found
In this free webinar, learn about the importance of early glycan screening for ensuring biologic quality, and how automation reduces time-to-insight and improves workflow efficiency. The featured speakers will share real-world applications and results from glycan screening success. Attendees will learn how to integrate automated glycan profiling into cell line development (CLD) labs. Early ...
Senese in Italy; and Karkinos Healthcare and Strand Life Sciences in India. The partnership with AstraZeneca will further catalyze the adoption of MSK-ACCESS® powered with SOPHiA DDM™. ...
In this free webinar, learn about the challenges in maintaining reliability, reproducibility and consistency in induced pluripotent stem cell (iPSC) cultures. Attendees will be introduced to a novel cell line restoration method supported by high-throughput single-cell cloning technologies. The featured speakers will explore the different types of quality control (QC) required for iPSCs with a ...
This potent combination empowers healthcare and life sciences organizations to navigate the complexities of system interoperability with unprecedented efficiency, enhanced performance, improved data integrity, and a more cost-effective, scalable infrastructure. Customers will be able to experience these benefits across a range of critical business functions, ...
In this free webinar sponsored by Advanced Instruments, gain insights into advances in monoclonal antibody production technology and manufacturing strategies. Attendees will learn why temperature and osmolality in cell culture are critical parameters affecting cell growth, viability and the concentration of HCPs in the supernatant. The featured speaker will discuss how temperature and osmolality ...
Data from pivotal PHOTON trial demonstrate long term efficacy of aflibercept 8 mg with extended intervals comparable to Eylea (aflibercept 2 mg) at fixed 8-weekly dosing over two years Patients assigned to a 16-week dosing regimen at baseline received a mean of 7.8 injections (6 fewer than Eylea) Safety profile of aflibercept 8 mg in diabetic macular edema (DME) remains comparable to Eylea ...
ByBayer AG
” The planned study will investigate finerenone compared to placebo in addition to standard of care in approximately 220 adults with CKD and T1D. Individuals will be randomized in a 1:1 ratio to receive either finerenone or placebo in addition to standard of care, consisting of a renin-angiotensin system (RAS)-blocking therapy such as an ...
ByBayer AG
Asundexian is an investigational agent and has not been approved by any health authority for use in any country, for any indication. It is currently being evaluated as a potential once-daily oral Factor XIa (FXIa) inhibitor in thrombosis prevention with the goal to reduce clot formation while leaving the body’s ability to respond to bleeding intact. ...
ByBayer AG
Thus, we welcome new research in extended treatment intervals that alleviate the situation for patients and the health care systems while achieving best visual acuity outcomes”, said Dr. ...
ByBayer AG
About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. ...
ByBayer AG
About Prostate Cancer at Bayer Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. ...
ByBayer AG
“Bayer is committed to improving health outcomes for people living with prostate cancerand that as many eligible patients as possible gain access to ...
ByBayer AG
SeqOne Genomics, provider of nextgeneration genomic analysis solutions for personalized medicine, announces the appointment of Hervé Pouzoullic as Chief Commercial Officer (CCO). He will lead the commercial development of the company to accelerate its growth and strengthen its international presence. Hervé has more than 25 years of experience in sales, business development and ...
Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PULSAR and PHOTON In both trials, aflibercept 8 mg demonstrated unprecedented durability results with treatment intervals of up to ...
ByBayer AG
“We are committed to improving prostate cancer care across all stages of the disease and recognize that for patients and their families, quality of life is just as critical as prolonging survival and delaying disease progression. ...
ByBayer AG
Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer New approval based on data from the pivotal Phase III ARASENS trial The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the oral androgen receptor inhibitor (ARi) darolutamide plus ADT in combination with docetaxel in the indication of ...
ByBayer AG
About Radiology at Bayer As a true life-science company with a heritage of over 100 years in Radiology, Bayer is committed to providing excellence, from innovative products to high-quality services, to support efficient and optimized patient care. ...
ByBayer AG
“An important part of our mission at Bayer is to transform prostate cancer care and improve patient outcomes at various stages of the disease. We are working to ensure that as many eligible patients as possible have the opportunity to benefit from ...
ByBayer AG
The collaboration with Bayer has its roots in 2019, when Blackford was among the selected start-ups of Bayer’s G4A Digital Health Partnerships Program that year. About Radiology at Bayer As a true life-science company with a heritage of over 100 years in Radiology, Bayer is committed to providing excellence, from innovative products to ...
ByBayer AG
Based on the positive results of both pivotal Phase III studies, FIDELIO-DKD and FIGARO-DKD, Kerendia™ was approved in March 2022 by the Japanese Ministry of Health, Labour, and Welfare (MHLW). Further regulatory approvals by other health authorities in multiple other countries have been granted or are currently pending following submissions for marketing ...
ByBayer AG